{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/69c1ce3a1a160b44dbcc0ce8?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Mike Curtis: Pig Organs as a Bridge to Human Transplants","description":"<p>Xenotransplantation has long been a scientifically promising but ethically complex field, overshadowed by its limited practicality despite the growing shortage of transplantable organs and the urgent needs of patients. Recent breakthroughs, including genetically modified pig heart transplants in 2022 and 2023, have demonstrated its feasibility, marking a turning point even though long-term survival has not yet been achieved. In this episode of <em>Behind the Breakthroughs</em>, Mike Curtis, PhD, President and CEO of eGenesis, explains how the company is building on this success to advance xenotransplantation as a scalable clinical strategy, emphasizing that even temporary extensions of life—such as a recent nine-month kidney transplant case—can provide meaningful outcomes and bridge patients to future treatments.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by Erick Ziegler</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p><p><br></p>","author_name":"Inside Precision Medicine"}